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Rationale: Knowledge on monoclonal antibody biodistribution in healthy tissues in humans can 
support clinical drug development. Molecular imaging with positron emission tomography can yield 
information in this setting. However, recent imaging studies have analyzed the behavior of single 
antibodies only, neglecting comparison across different antibodies.
Methods: We compared the distribution of four 89Zr-labeled antibodies in healthy tissue in a retro-
spective analysis based on the recently published harmonization protocol for 89Zr-tracers and our 
delineation protocol. 
Results: The biodistribution patterns of 89Zr-lumretuzumab, 89Zr-MMOT0530A, 89Zr-bevacizumab and 
89Zr-trastuzumab on day 4 after tracer injection were largely similar. The highest tracer concentration 
was seen in healthy liver, spleen, kidney and intestines. About one-third of the injected tracer dose 
was found in the circulation, up to 15% in the liver and only 4% in the spleen and kidney. Lower tracer 
concentration was seen in bone marrow, lung, compact bone, muscle, fat and the brain. Despite 
low tracer accumulation per gram of tissue, large-volume tissues, especially fat, can influence overall 
distribution: On average, 5-7% of the injected tracer dose accumulated in fat, with a peak of 19% in 
a patient with morbid obesity.
Conclusion: The similar biodistribution of the four antibodies is probably based on their similar 
molecular structure, binding characteristics and similar metabolic pathways. These data provide a 
basis for a prospectively growing, online accessible warehouse of molecular imaging data, which 
enables researchers to increase and exchange knowledge on whole body drug distribution and 
potentially supports drug development decisions.




In the last two decades, 28 monoclonal antibodies (mAb), an important class of targeted 
anti-cancer therapeutics, have been approved by the FDA and EMA for cancer therapy.1-4 The 
majority of these drugs were engineered to bind to a specific target. In addition, two antibody 
drug conjugates—mAbs loaded with a cytotoxic agent to specifically bring its cargo to cancer 
cells—are currently approved for use in patients. During the next decade much cancer drug 
development is expected to focus on antibodies or constructs based on antibodies, like 
antibody-drug conjugates, antibody fragments and bispecific antibodies.5 As a result, rational 
drug dosing choices for mAbs are a crucial focus of clinical research, especially because the 
maximum tolerated doses often cannot be established.
This research can be enhanced with molecular imaging, which enables whole body 
assessment of drug distribution in healthy and malignant tissue over time. Moreover, molecular 
imaging can potentially enhance understanding of drug pharmacokinetics and support dosing 
decisions in early clinical drug development.6 At present, nearly 20 mAbs have been coupled to 
various radionuclides and evaluated in early clinical trials using positron emission tomography 
(PET).6 Of the radionuclides currently available, zirconium-89 (89Zr) is increasingly being used 
to label mAbs. 89Zr is advantageous because it remains in cells after internalization of the mAb-
receptor complex, which leads to improved tumor image contrast via accumulation, and its 
half-life of about 78 hours allows target binding over a longer period of time, which better 
matches the long half-lives of mAbs.7 A head-to-head comparison of Indium-111-trastuzumab 
and 89Zr-trastuzumab in mice showed the favorable image quality of the 89Zr-labeled tracer and 
a comparable normal organ distribution, with as the only difference a higher normal bone tracer 
uptake at the latest scan moment for 89Zr-trastuzumab.8
Until now, imaging trials only focused on biodistribution analysis of single agents, neglecting 
comparison across different antibodies. The latter, however, might be of great value during 
drug development, especially in the era of immune checkpoint inhibitors, as those target 
lymphoid (effector) tissue exclusively or in combination with tumor tissue potentially resulting 
in a different distribution pattern. Drug dose decisions might be optimized based on deeper 
knowledge of distribution, the influence of the size and/or structure of the molecule itself or 
the target. To discern specifics in the biodistribution of single mAbs, general knowledge about 
mAb distribution is required. Thereby, the administered protein dose is of special interest, as 
monoclonal antibodies can show different pharmacokinetic and potentially target saturation 
might occur after administration of therapeutic doses. Furthermore, as also engineered 
antibodies and other constructs like bispecific antibodies or antibody fragments with potentially 
different kinetics and dynamics are introduced in the clinics, more detailed information on 




the currently used mAb might speed up gain of knowledge.9 Finally, molecular PET imaging 
with 89Zr-mAb tracers seems to have the potential to predict response to mAb drug treatment.10
Previous multicenter trials with fluorine-18 have shown the necessity of harmonization 
to reduce data variability and enable comparison of data between trials and sites, which led 
to development of the European Association of Nuclear medicine (EANM) guidelines and 
establishment of the EANM Research Ltd (EARL) accreditation.11, 12 For 89Zr, a comparable 
harmonization protocol has been developed only recently.13 Before this harmonization protocol 
became available, it was not possible to compare the biodistribution of 89Zr-labeled mAbs 
assessed by PET. Comparison between the biodistribution of antibodies was also hampered 
by the lack of a standard delineation protocol when performing the semi-quantitative analyses. 
Moreover, biodistribution of some mAbs assessed in clinical imaging studies was described as 
part of a detailed dosimetric analysis (e.g., 14), whereas other imaging trials used a standardized 
uptake value (SUV) based description of the biodistribution (e.g., 15-18). If we could make 
standardized comparisons, this would be an important step towards using molecular imaging 
data for optimizing rational drug development.
To support such inter-study comparisons, we decided to generate the basis of a prospectively 
growing mAb imaging data warehouse. To do so, we performed a comparative biodistribution 
analysis of four 89Zr-labeled mAbs that we previously explored in clinical studies: the anti-human 
epidermal growth factor receptor (HER) 2 antibody trastuzumab, the anti-HER3 antibody lumre-
tuzumab, the anti-vascular endothelial growth factor A (VEGF-A) antibody bevacizumab and the 
anti-mesothelin antibody MMOT0530A.15-18 This analysis was based on the 89Zr-harmonization 
protocol and was conducted according to the delineation protocol for 89Zr-tracers, which we 
recently established. We then deposited this data in an online warehouse. 
methods
Pet scan selection
For this analysis, we selected PET scans of patients following injection of the mAb tracers 89Zr-
lumretuzumab, 89Zr-MMOT0530A, 89Zr-bevacizumab or 89Zr-trastuzumab. These scans were 
obtained from clinical imaging trials (specified below) or from extended clinical work-ups and 
had been performed before start of treatment on patients with locally advanced or metastatic 
solid cancer. The inclusion criteria for the scans were as follows: administered tracer activity of 
37 MBq (± 10%), the PET scan had to be performed 4 days after tracer injection together with 
a low-dose computed tomography (LD CT) and the tracer had to be complemented with the 
previously determined optimal unlabeled imaging protein dose (100 mg lumretuzumab, 50 mg 
trastuzumab, 10 mg MMOT0530A or no unlabeled mAb in case of bevacizumab imaging).17-19 The 
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optimal unlabeled imaging protein dose was defined as the dose required to ensure sufficient 
tracer in the circulation 4 days after tracer injection for adequate tumor visualization. Patients and 
their corresponding PET scans were excluded from the biodistribution analysis if patient-related 
and/or disease-related factors were identified that might have influenced the biodistribution, 
like recurrent pleural effusion needing continuous drainage or a history of hemihepatectomy. 
Patients’ history, age, sex, weight and height were collected from their dossiers.
PET scans were performed in clinical imaging trials executed in the Department of Medical 
Oncology of the University Medical Center Groningen (UMCG, Groningen, the Netherlands) and 
of the VU University Medical Center (VUMC, Amsterdam, the Netherlands),17, 18 or as part of an 
extended clinical work-up. All clinical trials were approved by the responsible Medical Ethics 
Committee, as well as the Central Committee on Research Involving Human Subjects, and 
registered individually or as part of the corresponding phase I trial (ClinicalTrials.gov identifiers 
NCT01482377, NCT01832116 and NCT01028638).
Pet imaging 
PET acquisition at 4 days postinjection was carried out from head to upper thigh, in bed positions 
of 5 minutes per bed position with a PET/CT camera (Biograph mCT, Siemens [UMCG], and 
Gemini TF or Ingenuity TF, Philips [VUMC]). PET scans were accompanied by a LD CT scan for 
attenuation correction. All PET images were reconstructed using the harmonized reconstruction 
algorithm recommended for multicenter 89Zr-mAb PET scan trials.13 
89Zr-mAb Pet scan analysis
PET scans of all four tracers were analyzed using the software A Medical Imaging Data Examiner 
(AMIDE version 0.9.1; Stanford University, 20), in a standardized manner according to our 
delineation protocol (Supplementary Table 1). Spherical volumes of interest (VOI) with predefined 
sizes were drawn in healthy tissue in the brain, lung, liver, muscle, spleen, kidney, bone marrow, 
compact bone, fat and the intestine. A VOI in the aorta was used as readout for blood pool 
activity. Furthermore, all tumor lesions visible on PET and/or diagnostic CT scan were delineated 
per patient to estimate total tumor volume. In patients without liver metastases, the whole liver 
was manually delineated using the LD CT for anatomic reference to assess whole organ tracer 
uptake. A whole body VOI was drawn from head to the tuber ischiadicum to estimate the total 
amount of tracer left in the patient (excluding the legs).
For all VOIs, the percentage injected dose per kilogram (%ID/kg), normalized to calibrated 
dose of the 89Zr-tracer, corrected for decay at the time of scanning, was calculated (Supplementary 
Table 1). The total tumor volume was estimated by the sum of single tumor volumes calculated 




results of the delineation of the whole liver were used to calculate the activity as percentage 
of the injected dose (%ID) in total fat and liver, respectively (Supplementary Table 1). To assess 
the activity (%ID) in the spleen, kidneys and total blood volume, the volumes of the spleen and 
the kidneys were estimated based on linear CT measurements,23, 24 and the total blood volume 
was calculated using Nadler’s formula.25 
statistics
Statistical analyses were performed using IBM SPSS Version 22. In case of normally distributed 
data, groups were compared using a one-way ANOVA with either post hoc Gabriel or Games-
Howell test depending on homogeneity of variances as assessed by Levene’s test. If results 
were not normally distributed, comparison was performed using a Kruskal-Wallis followed by 
a Mann-Whitney U test. P ≤ 0.05 was considered to be a significant difference. All analyses were 
2-sided. Bivariate correlations were performed using Pearson correlation coefficients. Data are 
presented as mean ± standard deviation (SD), unless otherwise stated. 
results
Patient characteristics 
For 89Zr-lumretuzumab, 89Zr-MMOT0530A, 89Zr-bevacizumab and 89Zr-trastuzumab, scans of 
eleven, nine, ten and nine patients, respectively, were eligible for comparative 89Zr-tracer 
biodistribution analysis (Fig. 1). Per tracer, we analyzed the same number of scans (n = 9). If 
Figure 1 Scan selection per tracer according to predefined eligibility criteria. a Optimal imaging dose of 
unlabeled lumretuzumab was considered 100 mg, scans with 10 and 50 mg were excluded. b The scans of 
patients with a history of a hemihepatectomy (n = 1) and recurrent pleural effusion needing continuous 
drainage (n = 1) were excluded.
89Zr-MMOT0530A (n = 11)
Excluded (n = 2)
89Zr-bevacizumab (n = 13) 89Zr-trastuzumab (n = 13) 89Zr-lumretuzumab (n = 20)
Assessed for eligibility:
Eligible n = 9 Eligible n = 10 Eligible n = 9 Eligible n = 11
Analyzed n = 9 Analyzed n = 9 Analyzed n = 9 Analyzed n = 9
< optimal unlabeled 
imaging protein dose 
(n = 2) 
•
Excluded (n = 3)
No LDCT (n = 3) •
Excluded (n = 4)
< optimal unlabeled 
imaging protein dose 
(n = 2)
< 37 ± 10% MBq 
(n = 1)
No LDCT (n = 1)
•
Excluded (n = 9)
< optimal unlabeled 
imaging protein dose 
(n = 4) a
< 37 ± 10% MBq 
(n = 1)
No day 4 scan (n = 2)
Patient/disease 
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Age, median years (range) 59 (48-72) 62 (44-70) 64 (51-68) 47 (22-73)
Number of patients 9 9 9 9
Male 5 (56) 2 (22) 5 (56) 2 (22)
Female 4 (44) 7 (78) 4 (44) 7 (78)
Tumor type, n (%)
Colorectal 5 (56) - - 1 (11)
Breast 1 (11) - - 8 (89)
Oropharyngeal 1 (11) - - -
CUP 1 (11) - - -
Vulvar 1 (11) - - -
Ovarian - 2 (22) - -
Pancreatic - 7 (78) - -
Renal cell - - 9 (100) -
Sites of tumor lesions, n c
Adrenal gland 3 3 3 -
Bone 1 - 40 121
Brain - - 2 9
Breast - - - 2
Intestine 2 - 2 1
Kidney - - 16 -
Lung 34 3 6 2
Liver - 7 7 48
Lymph nodes 10 6 9 27
Pancreas - 4 4 -
Pleura 2 - 3 -
Soft tissue d 10 6 29 6
Spleen - - 1 1
Thyroid gland - - 2 -
Uterus - 2 - -
Tumor load, mL (± SD) 41 (± 25) 42 (± 22) 116 (± 67) 99 (± 133)
a 89Zr-lumretuzumab PET was performed in patients with HER3-positive disease according to study protocol 
(Meulendijks et al., CCR 2017). b 89Zr-trastuzumab PET was performed in patients with HER2-postive disease 
as part of an extended clinical work-up. c Sites of tumor lesions comprise sites of primary tumors and sites of 
metastases at the time of PET imaging. d Soft tissue lesions include subcutaneous lesions not further specified, 
intramuscular lesions and abdominal soft tissue lesions. CUP, cancer of unknown primary.
more than 9 scans were available, the first 9 of all eligible PET scans were selected. Additional 
information on the mAbs and the respective 89Zr-tracers are summarized in Supplementary 
Table 2. The analyzed PET scans were performed between November 2009 and August 2014. 
Included patients had locally advanced or metastatic cancer, the majority of the patients had 




89Zr-mAb tracer distribution in healthy tissue
All tracers showed a comparable distribution pattern throughout the whole body with the 
highest tracer uptake (calculated as %ID/kg) in healthy liver tissue, as well as in the spleen, 
kidneys and intestines (Fig. 2). Generally, lower tracer concentration was observed in the bone 
marrow, lung, compact bone, muscle, fat tissue and the brain (Table 2).
Figure 2 Representative maximum intensity projection of a PET scan 4 days after injection with 89Zr-
lumretuzumab (a), 89Zr-MMOT0530A (b), 89Zr-bevacizumab (c) and 89Zr-trastuzumab (d). The patients injected 
with 89Zr-bevacizumab (c) and 89Zr-trastuzumab (d) show clear tumor tracer uptake (black and white arrows), 
whereas tumor lesions on the 89Zr-lumretuzumab PET and 89Zr-MMOT0530A were visually negative.
a b
c d
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Healthy lung tracer uptake was the highest for 89Zr-MMOT0530A compared to the other 
tracers with a mean of 1.7 (± 0.7) %ID/kg (Fig. 3 and Table 2). Furthermore, lung uptake varied 
most between patients injected with 89Zr-MMOT0530A (range 0.8-3.1 vs. 0.9-1.3, 0.7-1.4 and 
0.5-2.0 for patients injected with 89Zr-lumretuzumab, 89Zr-bevacizumab and 89Zr-trastuzumab, 
respectively). Also uptake in healthy liver tissue, compact bone and bone marrow was the 
highest for 89Zr-MMOT0530A (10.8 ± 3.6, 1.2 ± 0.3 and 2.9 ± 0.5 %ID/kg). In the intestine, likely 
influenced by fecal content, as well as in healthy renal tissue, the highest activity, representing at 
least partially excretion, was observed for 89Zr-trastuzumab (5.4 ± 2.4 and 8.7 ± 1.5 %ID/kg). For 
brain, spleen, muscle and fat tissue comparable uptake was observed between the four analyzed 
89Zr-mAb tracers. The remaining radioactivity present in the aorta (= readout for blood pool) 
was similar between all 89Zr-mAb tracers as a result of the added unlabeled antibody imaging 
dose selected in earlier trials. Blood pool activity did not correlate with the tumor load for 89Zr-
lumretuzumab, 89Zr-bevacizumab and 89Zr-MMOT0530A, and only poorly for 89Zr-trastuzumab 
(r2 = 0.46, Supplementary Fig. 1).
Table 2 Normal tissue tracer uptake as percent of injected dose per kilogram bodyweight per 89Zr-
monocloncal antibody tracer 4 days post tracer injection
Tissue












Aorta 6.2 (± 1.6) 7.5 (± 1.3) 7.1 (± 1.6) 7.7 (± 2.8) 0.35
Bone marrow 1.9 (± 0.6) 2.9 (± 0.5) 2.1 (± 0.7) 2.8 (± 1.0) 0.02 a
Brain 0.1 (± 0.1) 0.3 (± 0.2) 0.2 (± 0.1) 0.3 (± 0.1) 0.09
Compact bone 0.9 (± 0.6) 1.2 (± 0.3) 0.6 (± 0.2) 0.8 (± 0.4) 0.01 b
Fat tissue 0.2 (± 0.1) 0.2 (± 0.1) 0.2 (± 0.2) 0.3 (± 0.1) 0.26
Intestine 3.4 (± 1.5) 3.9 (± 1.5) 2.7 (± 1.5) 5.4 (± 2.4) 0.02 c
Kidney 5.4 (± 0.6) 7.6 (± 1.6) 6.1 (± 1.1) 8.7 (± 1.5) < 0.01 d
Liver 7.3 (± 1.3) 10.8 (± 3.6) 9.9 (± 1.4) 6.8 (± 1.6) < 0.01 e
Lung 1.1 (± 0.1) 1.7 (± 0.7) 1.1 (± 0.2) 1.4 (± 0.4) 0.02 a
Muscle 0.7 (± 0.2) 0.8 (± 0.2) 0.7 (± 0.2) 0.8 (± 0.3) 0.36
Spleen 5.0 (± 1.2) 5.8 (± 1.8) 4.6 (± 0.8) 5.1 (± 1.6) 0.32
a Post hoc analysis showed no significant difference between the four groups. b Significant difference 
between 89Zr-MMOT0530A and 89Zr-bevacizumab. c Significant difference between 89Zr-bevacizumab and 89Zr-
trastuzumab. d Significant difference between 89Zr-lumretuzumab and 89Zr-MMOT0530A, 89Zr-lumretuzumab 
and 89Zr-trastuzumab, 89Zr-bevacizumab and 89Zr-trastuzumab, and 89Zr-MMOT0530A. e Significant difference 
between 89Zr-lumretuzumab and 89Zr-bevacizumab, 89Zr-bevacizumab and 89Zr-trastuzumab, and 89Zr-




Amount of tracer in healthy tissue, as percentage of injected dose
There was no difference between the total amount of 89Zr-lumretuzumab, 89Zr-bevacizumab and 
89Zr-trastuzumab remaining in the body on day 4 after tracer injection (69.5 ± 7.1, 69.9 ± 6.3 and 
67.9 ± 6.1 %ID, respectively). The remaining activity in patients injected with 89Zr-MMOT0530A 
was higher compared to the other three tracers (85.8 ± 8.5 %ID) (Fig. 4).
Figure 3 Tracer uptake (%ID/kg) per healthy tissue and in blood for 89Zr-lumretuzumab, 89Zr-MMOT0530A, 89Zr-
bevacizumab and 89Zr-trastuzumab (left to right) 4 days post tracer injection. Each dot represents an individual 
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5A mean of 34.5 (± 8.4), 33.5 (± 3.7), 34.0 (± 5.7) and 30.9 (± 12.5) %ID was still circulating in 
the blood 4 days after administration of 89Zr-lumretuzumab, 89Zr-MMOT0530A, 89Zr-bevacizumab 
and 89Zr-trastuzumab, respectively (Table 3 and Fig. 5). In patients without liver metastases on 
average 10.3 (± 1.2, 89Zr-trastuzumab) %ID up to 14.0 (± 0.7, 89Zr-MMOT0530A) %ID accumulated 
in the liver 4 days post injection (n = 5, 3, 4 and 3 patients who received, respectively, 89Zr-
lumretuzumab, 89Zr-MMOT0530A, 89Zr-bevacizumab and 89Zr-trastuzumab). The total liver uptake 
ranged from 8.5 %ID to 16.0 %ID (Fig. 6). Despite the relatively high tracer concentration in the 
Figure 4 Radioactivity as %ID left in the body (head to tuber ischiadicum) 4 days postinjection per tracer. Each 
dot represents individual patients and asterisk indicates differences between groups with P < 0.05.
Table 3 Activity as part of the injected dose per 89Zr-monocloncal antibody tracer 4 days post tracer 
injection
Tissue









Total blood pool 34.5 (± 8.4) 33.5 (± 3.7) 34.0 (± 5.7) 30.9 (± 12.5)
Liver 11.7 (± 2.3) 14.2 (± 0.7) 13.5 (± 2.4) 10.3 (± 1.2)
Spleen 1.8 (± 1.0) 1.4 (± 0.5) 0.9 (± 0.2) 1.0 (± 0.1)
Kidney 1.0 (± 0.4) 1.1 (± 0.3) 1.6 (± 0.9) 1.1 (± 0.1)
Fat tissue 7.4 (± 5.1) 7.0 (± 2.2) 5.4 (± 2.4) 4.9 (± 2.7)
Tumor 0.1 (± 0.1) 0.4 (± 0.3) 0.3 (± 0.2) 0.9 (± 1.8)




spleen (up to 5.8 ± 1.8 %ID/kg) and kidney (up to 8.7 ± 1.5 %ID/kg), the absolute proportion of 
tracer accumulating in these organs was only 0.6 to 3.3 %ID for the spleen and 0.4 to 3.9 %ID 
for one kidney (Fig. 7). Tracer concentration in fat tissue, in contrast, was low compared to other 
healthy tissues: 0.2 (± 0.1), 0.2 (± 0.1), 0.2 (± 0.2) and 0.3 (± 0.1) %ID/kg for 89Zr-lumretuzumab, 
Figure 5 Mean uptake as %ID per 89Zr-monoclonal antibody tracer in blood, liver, spleen, kidney, fat, tumor, 
remaining tissues (including intestines), as well as excreted part and the legs.
 
Figure 6 Radioactivity as %ID in the liver without metastatic disease could be assessed in 5, 3, 4 and 3 patients 
injected with 89Zr-lumretuzumab, 89Zr-MMOT0530A, 89Zr-bevacizumab and 89Zr-trastuzumab, respectively.
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89Zr-MMOT0530A, 89Zr-bevacizumab and 89Zr-trastuzumab, respectively. Despite this generally 
low tracer concentration in fat, when the total amount of fat tissue in the patient was considered, 
a substantial proportion of the injected tracer dose accumulated in fat tissue: 7.4 (± 5.4), 7.0 (± 
2.2), 5.4 (± 2.6) and 4.9 (± 2.8) %ID of 89Zr-lumretuzumab, 89Zr-MMOT0530A, 89Zr-bevacizumab and 
89Zr-trastuzumab, respectively; Fig. 5. The estimated total amount of tracer accumulated in fat 
tissue ranged between 1.56 %ID and 18.95 %ID depending on the physique of the patient (Fig. 7).
The median measurable tumor load was 41 (± 25) mL, 42 (± 22) mL, 116 (± 67) mL and 99 
(± 133) mL for 89Zr-lumretuzumab, 89Zr-MMOT0530A, 89Zr-bevacizumab and 89Zr-trastuzumab, 
respectively (Table 1). In this dataset, on average per tracer less than 1 %ID accumulated in 
tumor lesions per patient (Table 3).
dIscussIon
We conducted the first comparative analysis of the healthy tissue distribution of four 89Zr-
mAb tracers, based on the recently published harmonization protocol for 89Zr 13 and analyzed 
according to our delineation protocol for 89Zr-mAb tracers.
89Zr-lumretuzumab, 89Zr-MMOT0530A, 89Zr-bevacizumab and 89Zr-trastuzumab showed a 
similar healthy tissue distribution pattern, with highest uptake in the liver, spleen and kidneys 





and lower uptake in the bone marrow, lung, compact bone, muscle, fat tissue and the brain. 
Tissues with generally low uptake can also be of interest with regards to distribution if the 
respective tissue comprises a larger volume, potentially influencing (optimal) tumor targeting. 
Fat tissue, for example, had one of the lowest uptake values in our dataset. However, depending 
on the physique of the patient, up to 19 %ID accumulated in fat. In comparison, the liver, 
which often is considered as sink organ by visual analysis due to its high tracer uptake per kg 
tissue, contained about 10-15 %ID and the spleen and one kidney account for a maximum 
of 4 %ID each, whereas less than 1 %ID accumulated in tumor lesions. The observed slight 
differences in healthy tissue distribution between the four analyzed 89Zr-mAb tracers might be 
the consequence of target specific uptake, non-specific tracer accumulation and/or clearance 
mechanisms specific for the certain mAb.
89Zr-MMT0530A uptake, compared to the other three tracers, was higher in the lung, which 
might partly be explained by the expression of mesothelin in mesothelial cells e.g. in the lining 
of the pleura,26, 27 whereas higher uptake in the liver, compact bone and bone marrow cannot 
be explained by the known protein expression profile. HER2 expression in and tracer excretion 
via the intestinal and urinary tract, in contrast, might have influenced 89Zr-trastuzumab uptake 
in the respective healthy tissues.28 Different from studies on 111Indium-trastuzumab performed 
shortly after cardiotoxic anthracycline treatment, in the present study cardiac HER2 expression 
was not visualized by 89Zr-trastuzumab PET. This was probably due to a receptor expression level 
that was below the PET-detectable threshold in the unstressed heart of the imaged patient 
population.29, 30
The location of the target itself, either in the cell membrane or in the surroundings of the 
tumor, did not seem to have much influence on the healthy tissue distribution of the four 
analyzed tracers; 89Zr-bevacizumab, which targets a non-membrane-bound growth factor, 
showed the same pattern as the other three mAbs that bind to membranous receptors. Besides 
tumor localized target, circulating target e.g., as soluble receptor or expressed by circulating 
tumor cells could also influence tracer kinetics. For all four targets, circulating variants have 
been described, but the impact of this fraction on drug kinetics, however, is unclear.31-34 Next 
to the ability of the analyzed mAbs to internalize in tumor cells, which was also indicated 
for bevacizumab,35 the absolute amount of target expressed, which is largely influenced by 
overall tumor load, might affect mAb tracer kinetics. In our dataset, however, the proportion 
of tracer localized at tumor sites was quite low, probably due to the low mean tumor load of 
the selected patients. At least for trastuzumab, it has been shown previously that tumor load 
clearly influences tracer and drug kinetics.36
Tracer distribution in healthy organs might also be influenced by non-target specific factors, 
such as the amount of tracer available in the blood, as well as metabolism and excretion.37, 38 
Together with the 89Zr-labeled mAb, a dose of unlabeled protein, which had been determined 
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in the previous imaging trials with the respective mAb, was injected. The unlabeled protein 
dose increases tracer availability over time, which is necessary with mAbs with dose-depending 
kinetics like trastuzumab.36, 39 Per tracer, the optimal unlabeled protein dose for baseline imaging 
was selected to assure comparable activity concentration in the blood of all four tracers over 
time. However, with all analyzed tracers apart from 89Zr-MMOT0530A, PET imaging has also been 
performed after administration of pharmacodynamics-active doses or the actual therapeutic 
dose.15, 16, 40 Thereby, normal organ distribution was comparable between baseline imaging 
and on-treatment imaging, whereas tumor uptake changed over time. Next to the unlabeled 
protein dose, the amount of endogenous neonatal Fc receptor (FcRn) might also influence the 
circulation time of therapeutic immune globulin G (IgG) molecules by protecting them from 
fast degradation, resulting in a long half-life of more than 20 days.41, 42 All four mAbs are IgG1 
molecules, so binding specifications to the FcRn are expected to be comparable, potentially 
explaining the similar biodistribution (Supplementary Table 2).
Due to their size, monoclonal antibodies like the ones studied here, are metabolized first to 
peptides and amino acids before being re-used for protein synthesis or excreted via the kidneys.42 
Several target and non-target specific mechanisms, as well as proteolysis by the liver and the 
reticuloendothelial system, contribute to mAb elimination. Advanced mAb engineering such 
as glycosylation can increase uptake and metabolism of mAbs by hepatic non-parenchymal 
Kupffer cells located in the liver, which might explain the relatively higher healthy liver tracer 
uptake.42, 43 After elimination, non-used remnants like the radionuclide can be excreted via the 
intestinal tract or potentially accumulate in compact bone or bone marrow, as visualized by 
PET. Furthermore, differences in tracer intactness over time might explain the differing uptake 
in compact bone.
The scientific community is becoming increasingly aware of the many benefits of data 
sharing.44 An example of the usefulness of data sharing is provided by the RECIST criteria, 
which after development have been verified by a warehouse containing data from numerous 
trials.45 With this first comparative analysis of four 89Zr-labeled mAb we aimed to create a basis 
for a prospectively growing warehouse of molecular imaging data of antibody-based tracers 
that will enable researchers worldwide to enhance and share their knowledge on whole body 
drug distribution. Therefore, all researchers in the field of molecular imaging are encouraged to 
add data to this developing warehouse as only expansion of the available data is expected to 
deliver a valuable long-term gain of knowledge. A short description on how to share or request 
imaging data are provided in Supplementary Table 3. We aim to add data from ongoing and 
planned imaging trials assessing molecules belonging to another IgG subclass, with different 
molecule size or structure, will be added to this warehouse in the future. Potentially target 
saturation can occur with higher antibody doses than used for baseline imaging and changes 




comparison of biodistribution of the same antibody with varying unlabeled antibody doses 
for imaging will be of interest as well. 
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Supplementary Figure 1 Correlation between activity in the aorta (%ID/kg) and tumor load (mL) for 89Zr-
lumretuzumab (r2 = 0.00, P = 0.93), 89Zr-MMOT0530A (r2 = 0.09, P = 0.44), 89Zr-bevacizumab (r2 = 0.11, P = 0.38) 




Supplementary Table 1 Standard delineation protocol 
1. Reconstruction method
According to Makris et al.1
2. Analysis plan
PET image analysis of scans performed 4 days post tracer injection. 
Targets to select for PET quantification
•	 Tumor lesions 
•	 Background regions (=healthy organs/tissue)
•	 Whole organs
PET quantification parameters
•	 Background regions: %ID/kg
•	 Tumor lesions: volume (mL)
•	 Whole organs: %ID/kg
Software
•	 A medical imaging data examiner (AMIDE, 2)
Targets
Lesions
•	 All visible lesions on PET and/or on diagnostic CT scan 
Background regions
•	 For each background organ a background area should be quantified.
•	 Use an sphericalVOI (location and/or size of VOI might be adapted in case of tumor locations) 
in at least 3 consecutive axial planes:
 - Brain 5 cm (left hemisphere, parietal) 
 - Lung 5 cm (right upper lobe, mediolateral) 
 - Aortic blood pool 2 cm (Aortic arch or thoracic aorta, highest region)
 - Muscle 5 cm (region right gluteus maximus/medius)
 - Spleen 5 cm (representative region; 4 cm if 5 cm VOI is too big) and 2 cm (highest region)
 - Liver 5 cm (representative region)
 - Kidney 2 cm (cortex of left kidney, highest region)
 - Bone marrow 2 cm (L4 or L5)
 - Bone cortex 1 cm (femur cortex, right)
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 - Intestine 2 cm (highest region)
 - Fat tissue 2 cm (abdominal region)
Whole organ analysis
•	 Only assess organs when there is no metastatic disease located in this certain organ
•	 Organs of interest for whole organ analysis:
 - Liver
Calculations
AMIDE output (mean activity concentration in Bq/cc) was used to calculate the percentage 
injected dose per kilogram (%ID/kg) tissue of every VOI with the following formula: 
Injected activity was corrected for decay between moment of tracer injection and time of 
scanning (under the assumption of a tissue density of 1 kg/L). 
Percentage organ and fat tissue tracer uptake was calculated using the following formula:











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary Table 3 Details on deposited data and curation process 
Data deposit
An overview over the deposited datasets including details on the dataset, contact 
information, information on requesting and depositing data can be found online under www.
imagingwarehouse.eu.
Deposited data
Information on the individual subject and imaging data per individual subject will be deposited. 
Specification of the deposited data for the four 89Zr-mAb tracers analyzed in the current 
manuscript:
Patient related information: 
Weight, height, total tumor load (PET based, mL), injected [netto] dose, time between tracer 
injection and start of PET scan, activity on the day of tracer injection. 
PET imaging data per individual patient: 
AMIDE output and SUV calculations for blood and normal organ VOI’s: aorta, liver, kidney, 
fat tissue, muscle, brain, lung, spleen, intestine, femur cortex and bone marrow. 
AMIDE output per VOI includes median, mean, variance, standard deviation, minimum, 
maximum and size (mm3).
SUV calculations include SUVmean and SUVmax.
Data to be deposited by external parties should include at least above mentioned patient 
related information and PET related information. Thereby, the administered radiation dose 
is not restricted to 37 MBq, as the dose can vary. Information on the used analysis tool and/
or algorithm should also be deposited. Throughout time, requirements on which data to be 
deposited might change, therefore, it is recommended to consult the website for further 
instructions (www.imagingwarehouse.eu). 
Data request 
All data will be provided upon request. Requests can be send by email to the imaging warehouse 
group (imagingwarehouse@onco.umcg.nl). Data can be requested by health care professionals 
and all scientific personnel. Data is provided for research purpose only.
Re-processing of imaging data with other reconstruction protocols and additional information 
can be requested. Whether requested data can be provided, will be decided by the for the 
dataset responsible researcher or delegates (e.g. based on privacy laws).




All requests need to contain a specification of the requested data set, information on the 
requesting person or group including name of the responsible investigator, function and 
institution. Furthermore, a short description of the intended aim/research question is preferred.
Public disclosure and publication policy
Provenance of the data must be stated and data needs to be referenced to in all publications 
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